Dilated cardiomyopathy and potentially deadly digoxin

South African Medical Journal

Volumn 101, Issue 6, 2011, Pages 388-389

  Opie, Lionel H ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; ISOSORBIDE; SPIRONOLACTONE;

CARDIAC RESYNCHRONIZATION THERAPY; CONGESTIVE CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DRUG BLOOD LEVEL; EDITORIAL; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HYPOKALEMIA; KIDNEY FAILURE; SINUS RHYTHM;

ATRIAL FIBRILLATION; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; DIGOXIN; HEART FAILURE; HUMANS;

EID: 79958057516     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. Sliwa K, Wilkinson D, Hansen C, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet 2008;371:915-922.
2. Ntusi NBA, Wonkam A, Shaboodien G, Badri M, Mayosi BM. Frequency and clinical genetics of familial dilated cardiomyopathy in Cape Town: Implications for the evaluation of patients with unexplained cardiomyopathy S Afr Med J 2011;101:394-398 (this issue).
3. Ntusi NBA, Badri M, Gumedze F, Wonkam A, Mayosi BM. Clinical characteristics and outcomes of familial and idiopathic dilated cardiomyopathy in Cape Town: A comparative study of 120 cases over 14 years. S Afr Med J 2011;101:399-404 (this issue).
4. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
5. Fauchier L, Grimard C, Nonin P, et al. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Am J Cardiol 2009;103:248-254.
6. Poole-Wilson P, Opie LH. Acute and chronic heart failure: positive inotropes, vasodilators and digoxin. In: Opie LH, Gersch BJ, eds. Drugs for the Heart. 7th ed. Philadelphia: Elsevier Saunders, 2009: 160-197.
7. Georgiopoulou VV, Kalogeropoulos AP, Giamouzis G, et al. Digoxin therapy does not improve outcomes in patients with advanced heart failure on contemporary medical therapy. Circ Heart Fail 2009;2:90-97.
8. Agarwal AK, Venugopalan P. Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. Eur J Heart Fail 2001;3:437-440.
9. Ahmed A, Pitt B, Rahimtoola SH, et al. Effects of low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol 2008; 123:138-146.
10. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentrations and outcomes in patients with heart failure. JAMA 2003;289:871-878.
11. Eichhorn EJ, Gheorghiade M. Digoxin-new perspectives on an old drug. N Engl J Med 2002;347:1394-1395.
12. Biggar RJ, Wohlfahrt J, Oudin A, et al. Digoxin use and the risk of breast cancer in women. J Clin Oncol 2011; Mar 21. [Epub ahead of print]
13. Ahren TP, Lash TL, Sørensen HT, et al. Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study. Breast Cancer Res 2008;10:R102.